

(b)(4)

(b)(4)

Total Amount of the Agreement:

(b)(4)

Total Estimated Government Funding of the Agreement:

(b)(4)

Total Estimated Recipient Funding of the Agreement:

(b)(4)

Funds Obligated:

(b)(4)

Period of Performance: September 30, 2017 through March 31, 2026 (Changed)

Authority: Section 319L(c) (4) (B) and/or 319L(c) (4) (D) of the Pandemic and All-Hazards Preparedness Act, P.L. 109-417

(b)(4)

(b)(4)

(b)(4)




Beginning with the effective date of this modification, the Government and Other Transaction Agreement holder mutually agree as follows:

- 1. Agreement No.:  
HHSO100201700020C Line Items and corresponding values:

Funding for this OTA is revised as follows:

<b>Line Item</b>	<b>Recipient</b> <i>Cost Share</i>	<b>Government</b> <i>Cost Share</i>	<b>Total Estimated</b> <b>Cost</b>	<b>Total</b> <b>Government</b> <b>Funds</b> <b>Obligated to</b> <b>Date</b>
------------------	---------------------------------------	----------------------------------------	---------------------------------------	-----------------------------------------------------------------------------------------

(b)(4)



**Note:**

(i) (b)(4)

(ii) External (Subrecipient or Affiliates) Expenses. External expenses will be billed based on actual third-party charges submitted to Regeneron.

(iii) (b)(4)

(iv)

2. Under Article II PERIOD OF PERFORMANCE, delete and replace as follows:

Line Item	Description of Services	Period of Performance
(b)(4)		

3. Under **ATTACHMENT 2, REPORTING REQUIREMENTS**, add three deliverables as follows:

**Unless otherwise stated, each deliverable in the table below shall be provided as one (1) electronic copy to the COR, CS, and CO.**

**In addition to or in replacement of electronic copies, the CO may direct the Contractor to submit the below deliverables via BARDA Digital Resources Portal in machine readable format.**

CDRL#	Deliverable	Deliverable Description	Reporting Procedures and Due Dates
01.6	(b)(4)	Upon request of the Government relating to COVID-19, the Contractor shall participate in regular updates with the project staff (via teleconference or email). Contractor will respond in a timely fashion (if reasonable and practicable under the circumstances, within the same day as the request).	<p>No agenda will be required for the meeting</p> <p>No meeting minutes are required</p>

		<p>(b)(4)</p> <p>The updates will address the content reasonably requested by BARDA and in the possession of, and reasonably accessible to, Regeneron, including key cost, schedule and technical</p> <p>(b)(4)</p> <p>provide the update in both confidential and non-confidential formats.</p> <p>Updates may occur on weekdays, excluding federal holidays. Upon request of the Government, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours' notice.</p>	<p>Contractor will provide updates verbally, in bulleted emails or other mutually agreed formats</p>
02.8	<p>Product Development Source Material and Manufacturing Report for COVID-19 Programs</p>	<p>(b)(4) the Contractor shall submit a spreadsheet regarding critical project materials. The form and content of the spreadsheet will be similar to past updates</p> <p>(b)(4)</p>	<ul style="list-style-type: none"> <li>Contractor will submit Product Development Source Material Report</li> </ul> <p>Within 30 business days of contract award</p> <p>Within 30 business days of substantive changes are made to sources and/or materials</p> <p>The Government will provide written comments to the Product Development Source Material and Manufacturing Report within 15 business days after the submission</p> <p>If corrective action is recommended, Contractor will respond to such concerns in writing</p>

4. Attached are the following revised documents:

- 1) Delete and replace Attachment 1 – Revised Statement of Work (SOW) dated March 20, 2020 18 pages).
- 2) Delete and replace Attachment 6 - Requisition Table

All other terms and conditions remain the same.

FOR THE UNITED STATES OF AMERICA  
OFFICE OF ACQUISITION MANAGEMENT,  
CONTRACTS & GRANTS SECRETARY

(b)(6)



FOR Regeneron Pharmaceuticals, Inc.

(b)(6)



END OF MODIFICATION No. 0006 TO HHSO100201700020C